

**Abacavir**

## Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
 Oral > Solid: 300 mg tablet (as sulfate)

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

**Didanosine**

## Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
 Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered  
 powder for oral solution; 250 mg buffered powder for oral solution  
 Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered  
 chewable dispersible tablet; 100 mg buffered chewable dispersible tablet;  
 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable  
 dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg  
 unbuffered enteric coated capsule; 250 mg unbuffered enteric coated  
 capsule; 400 mg unbuffered enteric coated capsule

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

**Emtricitabine**

## Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
 Oral > Liquid: 10 mg per mL  
 Oral > Solid: 200 mg

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

**Lamivudine**

## Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
 Oral > Liquid: 50 mg per 5 mL  
 Oral > Solid: 150 mg tablet

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

**Stavudine**

## Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
 Oral > Liquid: 5 mg per 5 mL powder for oral solution  
 Oral > Solid: 15 mg; 20 mg; 30 mg

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

## Tenofovir disoproxil fumarate

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

## Zidovudine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion  
Oral > Liquid: 50 mg per 5 mL  
Oral > Solid > tablet: 300 mg  
Oral > Solid > capsule: 250 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified